CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference
30 July 2024 - 10:00PM
CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on
developing treatments for age-related neurologic disorders, today
announced that Company’s Management will participate in a fireside
chat at the Canaccord Genuity 44th Annual Growth Conference, to be
held in Boston, MA, and participate in one-on-one investor
meetings.
Presentation Details Format: Fireside ChatDate:
Tuesday, August 13, 2024Time: 12:30 PM ETWebcast Link:
https://wsw.com/webcast/canaccord98/crvo/2485318
The webcast of the fireside chat will be accessible in the
Investors section of the CervoMed website
https://www.cervomed.com/.
About CervoMedCervoMed Inc. (the “Company”) is
a clinical-stage company focused on developing treatments for
age-related neurologic disorders. The Company is currently
developing neflamapimod, an investigational, orally administered
small molecule brain penetrant that inhibits p38MAP kinase alpha.
Neflamapimod has the potential to treat synaptic dysfunction, the
reversible aspect of the underlying neurodegenerative processes
that causes disease in DLB and certain other major neurological
disorders. Neflamapimod is currently being evaluated in a Phase 2b
study in patients with DLB.
Investor Contact: PJ KelleherLifeSci
AdvisorsInvestors@cervomed.com617-430-7579
CervoMed (NASDAQ:CRVO)
Historical Stock Chart
From Sep 2024 to Oct 2024
CervoMed (NASDAQ:CRVO)
Historical Stock Chart
From Oct 2023 to Oct 2024